Formed and led cross functional teams who developed a world-class coordinating center and in-house reimbursement services program for a leading global biotechnology company.

Designed and launched the distribution strategy and comprehensive patient support solutions for patients prescribed the first known cure for Hepatitis C.

Played an instrumental role in delivering affordability solutions for patients and the portfolio of products helping >90% of HIV infected patients in the US.

Conducted research with account managers and customers to gauge market interest in a treatment paradigm-shifting biosimilar.

Launched virtual and in-home nursing services by executing fee-for-service contracts with leading rare disease specialty pharmacies.

Partnered with a pre-commercial pharmaceutical client on the submission of an emergency use authorization (EAU) for a COVID-19 neutralizing therapy.

Supported a patient education solution for patients in need of new insurance, financial assistance, and cost share subsidies during open enrollment season.

Enhanced the performance of trade and channel management teams after implementing cross-portfolio Contract Life Cycle Management solutions.

Strengthened long-term client partnerships resulting in a rapid expansion of the JM DREW team and capabilities during the COVID-19 pandemic.

Implemented eServices workflow solutions during the vendor transition of a patient assistance and free medication program.

Launched commercial and free goods distribution solutions for rare and orphan disease therapies requiring pregnancy monitoring, incremental clinical support, and ancillary supplies.

Designed and implemented Service Level Agreements (SLA) for pharmaceutical brand teams to secure ownership and accountability from internal support functions.